Henlius Has Denosumab Application Accepted In China
NMPA Also Currently Reviewing Adalimumab And Trastuzumab Filings
Shanghai Henlius Biotech has announced that China’s NMPA has accepted the firm’s filing for its HLX14 denosumab biosimilar. Meanwhile, the company has also announced dosing the first patient in a Phase II clinical trial of its novel HLX10 anti-PD-1 monoclonal antibody.
